Table 2 Logit Estimates of The Associates of a Rapid Trajectory of Price Increases in Generic Drugs. All Drugs
| Â | Coefficient | Std Error |
|---|---|---|
Panel A | ||
 Baseline Payment | −1.414*** | (0.198) |
 Affected by Merger | −0.750 | (0.506) |
 Average HHI | 0.000256*** | (0.00001) |
 Average Doses per quarter | −0.0001 | (0.000) |
 Average share of branded in market | 0.925 | (0.763) |
Panel B | ||
 Number of labelers (Reference: 0–4)) | ||
  5–9 | −0.206 | ((0.290) |
  10+ | −1.249** | (0.539) |
 Therapeutic Group (Reference: Miscellaneous) | ||
  Anti-Infective | 0.492 | (0.483) |
  Cancer | 0.683 | (0.922) |
  Cardiovascular | 0.795** | (0.373) |
  CNS | 0.467 | (0.318) |
  Hormones | −0.272 | (0.444) |
  Immunosuppressant | 2.256 | (1.389) |
 Maintenance Group (Reference: Both Primary and Acute) | ||
  Primarily Acute | 0.708** | (0.347) |
 Primarily Chronic | 0.474 | (0.431) |
 Constant | −2.036*** | (0.630) |
 Log Likelihood | − 307.161 |  |
 Pseudo R2 | 0.255 |  |
 Observations | 959 |  |